Bliss Gvs Pharma Ltd vs Glenmark Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Bliss GVS Pharma Ltd is ₹ 276.25 as of 30 Apr 15:30 . The P/E Ratio of Bliss GVS Pharma Ltd changed from 14.9 on March 2021 to 14.7 on March 2025 . This represents a CAGR of -0.27% over 5 yearsThe P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 13.5 on March 2021 to 41.5 on March 2025 . This represents a CAGR of 25.18% over 5 years The Market Cap of Bliss GVS Pharma Ltd changed from ₹ 1018 crore on March 2021 to ₹ 1238 crore on March 2025 . This represents a CAGR of 4.00% over 5 yearsThe Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 13108 crore on March 2021 to ₹ 43458 crore on March 2025 . This represents a CAGR of 27.09% over 5 years The revenue of Bliss GVS Pharma Ltd for the Dec '25 is ₹ 236.71 crore as compare to the Sep '25 revenue of ₹ 252.86 crore. This represent the decline of -6.39% The revenue of Glenmark Pharmaceuticals Ltd for the Dec '25 is ₹ 3945 crore as compare to the Sep '25 revenue of ₹ 6247 crore. This represent the decline of -36.85% The ebitda of Bliss GVS Pharma Ltd for the Dec '25 is ₹ 50.73 crore as compare to the Sep '25 ebitda of ₹ 51.94 crore. This represent the decline of -2.33% The ebitda of Glenmark Pharmaceuticals Ltd for the Dec '25 is ₹ 729.88 crore as compare to the Sep '25 ebitda of ₹ 1175 crore. This represent the decline of -37.89% The net profit of Bliss GVS Pharma Ltd changed from ₹ 22.11 crore to ₹ 24.78 crore over 7 quarters. This represents a CAGR of 6.73% The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 340.24 crore to ₹ 403.23 crore over 7 quarters. This represents a CAGR of 10.19% The Dividend Payout of Bliss GVS Pharma Ltd changed from 7.64 % on March 2021 to 7.64 % on March 2025 . This represents a CAGR of 0.00% over 5 yearsThe Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 4.28 % on March 2021 to 4.38 % on March 2025 . This represents a CAGR of 0.46% over 5 years .

About Bliss GVS Pharma Ltd

Bliss GVS Pharma Limited was originally incorporated as a Private Limited Company in the name of Bliss Chemicals & Pharmaceuticals India Private Limited in 1984.
The status converted into a Public Limited Company and the name of the Company was changed to Bliss Chemicals & Pharmaceuticals India Limited and further to Bliss GVS Pharma Limited on May 12, 2006. The Company is engaged in manufacturing, marketing, trading and export of pharmaceutical products.
The Company has its manufacturing facility at Palghar which is WHO GMP approved.
The business operates five cutting-edge production facilities that adhere to WHO-GMP, EU-MP, ISO 14001 and OHSAS 45001 standards. The company commenced its business in 1985.
In 1994 the company introduced a new pharmaceutical product VAGID. During the financial year ended 31 March 2014, Bliss GVS Pharma's R&D center, received approval from Government of India's Department for Scientific & Industrial Research (DSIR).

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977.
The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets.
The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities are located at Nasik, Colvale, Baddi, Nalagarh, Sikkim, Indore and Aurangabad in India. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
Its branded generics business has a significant presence in markets across emerging economies including India.

FAQs for the comparison of Bliss GVS Pharma Ltd and Glenmark Pharmaceuticals Ltd

Which company has a larger market capitalization, Bliss GVS Pharma Ltd or Glenmark Pharmaceuticals Ltd?

Market cap of Bliss GVS Pharma Ltd is 2,922 Cr while Market cap of Glenmark Pharmaceuticals Ltd is 67,884 Cr

What are the key factors driving the stock performance of Bliss GVS Pharma Ltd and Glenmark Pharmaceuticals Ltd?

The stock performance of Bliss GVS Pharma Ltd and Glenmark Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bliss GVS Pharma Ltd and Glenmark Pharmaceuticals Ltd?

As of May 4, 2026, the Bliss GVS Pharma Ltd stock price is INR ₹276.25. On the other hand, Glenmark Pharmaceuticals Ltd stock price is INR ₹2405.55.

How do dividend payouts of Bliss GVS Pharma Ltd and Glenmark Pharmaceuticals Ltd compare?

To compare the dividend payouts of Bliss GVS Pharma Ltd and Glenmark Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.